|
Author
|
Year
|
Country
|
Type of research
|
Sample size
|
Case group/control group
|
Average age
|
Male/female
|
Gold Standard
|
Sampling type
|
Threshold
|
Whether to exclude inflammatory diseases
|
Whether to set a control group
|
Prosthesis type
|
Typology of infection
|
|---|
|
Wang [21]
|
2020
|
China
|
Retrospective
|
157
|
51/106
|
64.6
|
70/87
|
MSIS
|
Serum
|
1220 ng/ml
|
Yes
|
Yes
|
NA
|
Chronic
|
|
Qin [22]
|
2019
|
China
|
Forward-looking
|
122
|
55/67
|
65.9
|
53/69
|
ICM
|
Serum
|
1170 ng/ml
|
Yes
|
Yes
|
NA
|
Chronic
|
|
Pannu [14]
|
2020
|
USA
|
Retrospective
|
111
|
89/22
|
70
|
62/49
|
ICM
|
Serum
|
850 ng/ml
|
No
|
Yes
|
NA
|
NA
|
|
Hu [23]
|
2020
|
China
|
Retrospective
|
77
|
40/37
|
60.8
|
37/40
|
MSIS
|
Serum
|
955 ng/ml
|
No
|
Yes
|
NA
|
NA
|
|
Shahi [12]
|
2017
|
USA
|
Forward-looking
|
195
|
86/109
|
59.7
|
101/94
|
ICM
|
Serum
|
850 ng/ml
|
No
|
Yes
|
NA
|
NA
|
|
Fu [19]
|
2019
|
China
|
Forward-looking
|
30
|
15/15
|
65.6
|
9/21
|
MSIS
|
Plasma
|
850 ng/ml
|
Yes
|
Yes
|
NA
|
NA
|
|
Li [13]
|
2019
|
China
|
Retrospective
|
565
|
95/470
|
NA
|
248/317
|
ICM
|
Plasma
|
1250 ng/ml
|
No
|
Yes
|
NA
|
NA
|
|
Huang [20]
|
2019
|
China
|
Retrospective
|
101
|
31/70
|
64.9
|
NA
|
ICM
|
Serum
|
850 ng/ml
|
Yes
|
Yes
|
NA
|
NA
|
|
Xiong [15]
|
2019
|
China
|
Forwardlooking
|
80
|
26/54
|
65.4
|
54/26
|
MSIS
|
Serum
|
756 ng/ml
|
Yes
|
Yes
|
NA
|
NA
|
|
Xu [24]
|
2019
|
China
|
Retrospective
|
318
|
129/189
|
NA
|
NA
|
ICM
|
Plasma
|
1020 ng/ml FEU
|
Yes
|
Yes
|
NA
|
NA
|
- The control group was the aseptic loosening group. NA = not applicable
